Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Down syndrome, caused by trisomy of chromosome 21, is the single most common risk factor for early-onset Alzheimer's disease. Worldwide approximately 6 million people have Down syndrome, and all these individuals will develop the hallmark amyloid plaques and neurofibrillary tangles of Alzheimer's disease by the age of 40 and the vast majority will go on to develop dementia. Triplication of APP, a gene on chromosome 21, is sufficient to cause early-onset Alzheimer's disease in the absence of Down syndrome. However, whether triplication of other chromosome 21 genes influences disease pathogenesis in the context of Down syndrome is unclear. Here we show, in a mouse model, that triplication of chromosome 21 genes other than APP increases amyloid-β aggregation, deposition of amyloid-β plaques and worsens associated cognitive deficits. This indicates that triplication of chromosome 21 genes other than APP is likely to have an important role to play in Alzheimer's disease pathogenesis in individuals who have Down syndrome. We go on to show that the effect of trisomy of chromosome 21 on amyloid-β aggregation correlates with an unexpected shift in soluble amyloid-β 40/42 ratio. This alteration in amyloid-β isoform ratio occurs independently of a change in the carboxypeptidase activity of the γ-secretase complex, which cleaves the peptide from APP, or the rate of extracellular clearance of amyloid-β. These new mechanistic insights into the role of triplication of genes on chromosome 21, other than APP, in the development of Alzheimer's disease in individuals who have Down syndrome may have implications for the treatment of this common cause of neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Trisomy of chromosome 21 promotes the intracellular and extracellular deposition of amyloid-β. (A and B) Intracellular amyloid-β deposition (82E1) was increased by trisomy in hippocampal CA3 pyramidal neurons in 4.5–6.5-month-old mice [ANOVA trisomy-tgAPP interaction F(1,31) = 5.125, P = 0.031] [Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.012; wild-type (WT) (black circles) n = 10, trisomic (blue squares) n = 10, tgAPP (red triangles) n = 10, trisomic;tgAPP (purple inverted triangles) n = 10]. (C) A trend for increased hippocampal Tris-soluble multimeric amyloid-β (82E1-82E1 ELISA) normalized to the sum of amyloid-β38, amyloid-β40 and amyloid-β42 in trisomic;tgAPP was observed [trisomy F(1,24) = 3.928, P = 0.059; tgAPP n = 8, trisomic;tgAPP n = 11)]. (D–I) Amyloid-β deposition (6F/3D) in the hippocampus was quantified at (D–F) 6 and (G–I) 16 months of age. Trisomy increases (E and H) the number of plaques [tgAPP–trisomy interaction F(1,77) = 6.744, P = 0.011, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.008, 16 months P = 0.003] and (F and I) the area covered by amyloid-β [tgAPP–trisomy interaction F(1,85) = 4.005, P = 0.049, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.097, 16 months P = 0.037] (6 months wild-type n = 8, trisomic = 8, tgAPP n = 15, trisomic;tgAPP n = 13; 16 months wild-type n = 16, trisomic = 9, tgAPP n = 13, trisomic;tgAPP n = 11). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were studied and sex was included as a factor in the ANOVA. Scale bar in A = 50 µm; D and G = 500 µm. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/c172967425154239b3614fe878be331a/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-1.jpg)
![Figure 2 Trisomy of chromosome 21 promotes the aggregation of amyloid-β. (A–F) Cortical proteins from 16-month-old mice were fractionated and 5 M guanidine hydrochloride soluble amyloid-β quantified by (A–E) Meso Scale Discovery Assay or (F) mass spectrometry. (A and B) No effect of trisomy on amyloid-β38 [tgAPP-trisomy interaction F(1,28) = 0.385, P = 0.540] or amyloid-β40 [tgAPP-trisomy interaction F(1,28) = 0.962, P = 0.355] was observed, (C) but significantly more amyloid-β42 was detected in trisomic;tgAPP mice [tgAPP-trisomy interaction F(1,28) = 5.573, P = 0.025] (Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.005, wild-type n = 6, trisomic = 6, tgAPP n = 13, trisomic;tgAPP n = 11). (D and E) No change in the amyloid-β38/42 ratio [trisomy F(1,19) = 0.072, P = 0.792] or amyloid-β40/42 ratio [trisomy F(1,19) = 0.047, P = 0.831] was observed. (F) The relative abundance of different forms of amyloid-β peptides was not altered by trisomy of chromosome 21 (tgAPP n = 12, trisomic;tgAPP n = 10). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a factor in the ANOVA. Aβ = amyloid-β; WT = wild-type.](https://figures.cochat.ai/paper-figures/7de3168d568a462da08e5c9eb594be35/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-2.jpg)
![Figure 3 Trisomy of chromosome 21 exacerbates APP/amyloid-β-associated cognitive deficits. (A and B) Exposure to a novel open field was used as a test of activity and habituation (6 months, wild-type n = 28, trisomic n = 28, TgAPP n = 20, trisomic;tgAPP n = 18). (A) Overall activity: ANOVA of distance travelled revealed a main effect of tgAPP [F(1,78) = 26.250, P < 0.001], trisomy [F(1,78) = 9.246, P = 0.003], and a tgAPP-trisomy interaction [F(1,78) = 7.818, P = 0.007] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P = 0.008). (B) The total distance moved declined with exposure time (1-min time bins) ANOVA: main effect of time bin [F(29,2262) = 12.399 P < 0.001]; an interaction of time bin × trisomy [ANOVA F(29,2262) = 1.789 P = 0.006], time bin × tgAPP [F(29,2262) = 1.560 P = 0.029] and time bin × trisomy;tgAPP [F(29,2262) = 1.983, P < 0.001] was observed by ANOVA. (C and D) A Y-maze spatial novelty preference task (1-min delay) was used as a test of activity and memory. (Cohort B 2–3 months and Cohort A 6–7 months, the effect of genotype was similar in both cohorts so data were combined for analysis, wild-type n = 45, trisomic n = 43, TgAPP n = 36, trisomic;tgAPP n = 26). (C) ANOVA of the number of arm entries (test phase), revealed a main effect of trisomy [F(1,89) = 50.360, P < 0.001], tgAPP [F(1,89) = 47.001, P < 0.001], and a tgAPP–trisomy interaction [F(1,89) = 31.720, P < 0.001] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P < 0.001). (D) A preference ratio of 0.5 indicates chance performance (black dotted line). ANOVA of novelty preference revealed a main effect of trisomy [F(1,89) = 10.144 P = 0.002], tgAPP [F(1,89) = 9.312 P = 0.003] and a tgAPP–trisomy interaction [F(1,89) = 5.736, P = 0.019] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001 and trisomic P = 0.010). Performance of tgAPP–trisomic mice was above chance (one-sample t-test t = 3.287 P < 0.001). (E) A discrete-trial, longitudinal spontaneous alternation task in a T-maze was used as a test of memory, 50% alternation represents chance performance (black dotted line) (2–3 months wild-type n = 29, trisomic n = 30, TgAPP n = 21, trisomic;tgAPP n = 17, 6–7 months wild-type n = 28, trisomic n = 29, TgAPP n = 20, trisomic;tgAPP n = 17, 15–16 months wld-type n = 27, trisomic n = 26, TgAPP n = 27, trisomic;tgAPP n = 11). ANOVA of alternation showed a main effect of trisomy [F(1,67) = 7.084 P = 0.010], and an interaction of tgAPP–trisomy [F(1,67) = 4.706, P = 0.034] (Bonferroni pairwise comparison trisomic;tgAPP with wild-type P = 0.032). Performance of tgAPP-trisomic mice was above chance (one-sample t-test, 2–3 months t = 5.884 P < 0.001, 6–7 months t = 5.378 P < 0.001, 15–16 months t = 6.495 P < 0.001). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.](https://figures.cochat.ai/paper-figures/0728074d79e94df39d2ed6dbe5f83fa1/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-3.jpg)
![Figure 4 Trisomy of chromosome 21 genes other than APP does not increase APP abundance nor alter β-CTF/α-CTF ratio. (A, B and D) Full-length APP (FL-APP), APP β-CTF and APP α-CTF were measured in cortex (wild-type n = 17, trisomic n = 16, tgAPP n = 24, trisomic;tgAPP n = 19) and hippocampus (wild-type n = 11, trisomic n = 12, tgAPP n = 24, trisomic;tgAPP n = 17) at 3 months of age. (A) Full-length APP was higher in tgAPP and trisomic;tgAPP compared with wild-type or trisomic mice [cortex F(1,68) = 87.667, P < 0.001, hippocampus F(1,56) = 94.301, P < 0.001]. Trisomy did not alter full-length APP [trisomy–tgAPP interaction, cortex F(1,68) = 0.483, P = 0.489, hippocampus F(1,56) = 2.457, P = 0.123]. (B and C) In male mice, APP-CTF/full-length APP ratio was altered (cortex tgAPP n = 17, trisomic;tgAPP n = 11, hippocampus tgAPP n = 14, trisomic;tgAPP n = 8) β-CTF/full-length APP (t-test cortex P = 0.005, hippocampus P = 0.0217) and α-CTF/full-length APP (t-test cortex P = 0.005 hippocampus P < 0.001). (D) Trisomy did not alter the β-CTF/α-CTF ratio in the cortex [trisomy F(1,37) = 0.065, P = 0.799] or hippocampus [trisomy F(1,37) = 1.082, P = 0.305]. (B) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. WT = wild-type.](https://figures.cochat.ai/paper-figures/3778828581a64b7596da739983aabf31/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-4.jpg)
![Figure 5 Trisomy of chromosome 21 genes other than APP does not alter α-/β-secretase activity. Trisomy did not alter (A) soluble β-APP abundance [trisomy F(1,24) = 0.790, P = 0.383, trisomy-tgAPP interaction F(1,24) = 0.773, P = 0.388, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14], (B and C) cortical BACE1 abundance [trisomy F(1,24) = 0.002, P = 0.963; trisomy–tgAPP interaction F(1,24) = 0.071, P = 0.792, wild-type n = 6, trisomic n = 6, TgAPP n = 9, trisomic;tgAPP n = 7], (D) BACE1 β-secretase activity [trisomy F(1,13) = 0.006, P = 0.941; trisomy–tgAPP interaction F(1,13) = 0.001 P = 0.971, wild-type n = 6, trisomic n = 6, TgAPP n = 4, trisomic;tgAPP n = 5], or (E) soluble α-APP abundance [trisomy F(1,27) = 0.041, P = 0.841; trisomy–tgAPP interaction F(1,27) = 0.002, P = 0.969, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14]. (C) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM. Both sexes were analysed and sex was included as a factor in the ANOVA. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/b3aef28883bf4eaa91210dbb2249b115/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-5.jpg)

![Figure 7 Trisomy of chromosome 21 modulates amyloid-β ratios in vivo independently of modulation of γ-secretase activity. (A–C) Tris-soluble amyloid-β38, amyloid-β40 and amyloid-β42 were measured by Meso Scale Discovery 6E10 Aβ Triplex assay in 2-month-old hippocampus (wild-type n = 24, trisomic n = 22, TgAPP n = 25 and trisomic;tgAPP n = 27). (A) Trisomy decreased amyloid-β38 [trisomy F(1,4) = 15.403, P = 0.017] and amyloid-β40 [trisomy F(1,11) = 6.359, P = 0.028], but amyloid-β42 was not changed [trisomy F(1,11) = 2.978, P = 0.112], (B) resulting in an alteration in the amyloid-β38/42 ratio [trisomy F(1,4) = 14.553, P = 0.019] and (C) the amyloid-β40/42 ratio [trisomy F(1,10) = 95.694, P < 0.001]. (D) Hippocampal amyloid-β40/42 ratio negatively correlates with the relative abundance of aggregated amyloid-β (multimeric 82E1-82E1 amyloid-β ELISA) (linear correlation, R2 = 0.5485, P = 0.0003, tgAPP n = 8, trisomic;tgAPP n = 11). Trisomy did not alter the carboxypeptidase activity of the γ-secretase complex, as measured by (E and G) amyloid-β38/42 and (F and H) amyloid-β40/42 ratios produced in vitro by the complex isolated from cortex from (E and F) the Tc1 trisomic mouse [trisomy amyloid-β38/42 F(1,11) = 4.88, P = 0.499; amyloid-β42/40 F(1,11) = 0.799, P = 0.395, wild-type = 9, trisomic = 9] and (G and H) people with Down syndrome and Alzheimer’s disease (AD-DS) (n = 6) compared with age- and sex-matched individuals who did not have Down syndrome or dementia (control n = 6) [trisomy amyloid-β38/42 F(1,5) = 0.102, P = 0.763; amyloid-β42/40 F(1,5) = 0.187, P = 0.684]. (A–F) Data are represented as mean ± SEM, (G and H) individual cases plotted, horizontal line indicates mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and females were studied and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.](https://figures.cochat.ai/paper-figures/ab4297bc73604e059748d7a5a4125e9e/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, it has been shown in preclinical models of DS-AD that triplication of HSA21 genes modulates Aβ aggregation and APP transgene-associated mortality independently of an extra copy of APP.17,18”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies have indicated that an additional copy of HSA21 genes can alter APP biology, including Aβ deposition in other APP transgenic models.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence in preclinical models demonstrates that genes other than APP being in three copies modify aspects of DSAD, such as cognition and amyloid-β load [1, 50, 70]”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [70]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In AD brain, markers of ER stress are elevated and correlate with progression of this disorder53,54,58.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [58]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In response to abnormal elevated levels of misfolded proteins and/or free Ca2+ in the ER lumen, the unfolded protein response (UPR) is engaged53,54,58.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“J20-tgAPP mice overexpress a human APP transgene with Alzheimer’s disease mutations and accumulates amyl- oid-b within the brain from (cid:5) 4–5 months of age (Mucke et al. , 2000).”
Preparation of PCR-Quality Mouse Genomic DNA with Hot Sodium Hydroxide and Tris (HotSHOT)
Truett, G. E., Heeger, P., Mynatt, R. L., Truett, A. A., Walker, J. A., & Warman, M. L. (2000) · BioTechniques · doi:10.2144/00291bm09 · Cited by 1,738 · cited 1×
“DNA was extracted from tail tip or ear biopsy by the Hot Shot method (Truett et al. , 2000).”
Rovelet-Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249 · cited 1×
“(Rovelet-Lecrux et al., 2006; Sleegers et al., 2006) making it likely that three copies of APP are important in the development of Down syndrome–Alzheimer’s disease.”
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 2×
“In vivo microdialysis In vivo microdialysis was used to assess brain interstitial fluid (interstitial fluid) amyloid-b40 half-life in awake mice as previously described (Castellano et al., 2011).”
MethodInfluentialSelf-citationTrafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 1×
“The first site of amyloid-b accumulation in people with Down syndrome is within the cell (Gouras et al., 2000; Gyure et al., 2001; Mori et al., 2002; Hirayama et al., 2003) in the endo- lysosomal system (Cataldo et al., 2000, 2004).”
BackgroundA mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 1×
“Ts65Dn or Dp(10)1Yey;Dp(16)1Yey;Dp(17)1Yey triple trisomic mice] do not form amyloid-b plaques even in elderly mice (26 months) (Reeves et al., 1995; Yu et al., 2010).”
T-maze alternation in the rodent
Deacon, R. M. J., & Rawlins, J. N. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.2 · Cited by 897 · cited 1×
“A T-shaped maze made of wood painted dark grey with 30 (cid:2) 10 (cid:2) 29 cm arms, with a central partition extending 7 cm into the start arm from the back of the maze, was used to assess spontaneous alternation as previously described (Deacon and Rawlins, 2006).”
The neurobiological basis of spontaneous alternation
Lalonde, R. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00041-0 · Cited by 838 · cited 1×
“We note that the performance of wild-type mice declined with age in this task, as has been previously reported (Lalonde, 2002).”
Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 776 · cited 1×
“The first site of amyloid-b accumulation in people with Down syndrome is within the cell (Gouras et al., 2000; Gyure et al., 2001; Mori et al., 2002; Hirayama et al., 2003) in the endo- lysosomal system (Cataldo et al., 2000, 2004).”
Background
Cited by
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 282
Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
Iulita, M. F., Garzón Chavez, D., Klitgaard Christensen, M., Valle Tamayo, N., Plana-Ripoll, O., Rasmussen, S. A., Roqué Figuls, M., Alcolea, D., Videla, L., Barroeta, I., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12910 · Cited by 195
Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years
Hithersay, R., Startin, C. M., Hamburg, S., Mok, K. Y., Hardy, J., Fisher, E. M. C., Tybulewicz, V. L. J., Nizetic, D., & Strydom, A. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3616 · Cited by 176
Self-citationAlić, I., Goh, P. A., Murray, A., Portelius, E., Gkanatsiou, E., Gough, G., Mok, K. Y., Koschut, D., Brunmeir, R., Yeap, Y. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0806-5 · Cited by 123
“dose of chromosome 21 to a mouse that several hundred fold overexpresses Aβ40 and 42 worsens the amyloid plaque load, and this correlates with an unexpected decrease in the Aβ40/42 ratio [41].”
Self-citationMullane, K., & Williams, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 105
Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein
Gómez, W., Morales, R., Maracaja‐Coutinho, V., Parra, V., & Nassif, M. (2020) · Aging · doi:10.18632/aging.102677 · Cited by 102
“Though APP is not triplicated, the triplication of other coding genes or ncRNAs from Chr21 was sufficient to increase the soluble Aβ42/Aβ40 ratio and worsen the cognitive decline in the DS/AD model associated with the AD [63].”
BackgroundFrom Neurodevelopmental to Neurodegenerative Disorders: The Vascular Continuum
Ouellette, J., & Lacoste, B. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.749026 · Cited by 98
“In rodent studies of DS-AD, triplication of chromosome 21 genes other than APP demonstrated increased Aβ aggregation deposition and cognitive deficits (Wiseman et al., 2018).”
BackgroundNeuropathology of Dementia Disorders
Schneider, J. A. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001137 · Cited by 106
Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework
Mentis, A.-F. A., Dardiotis, E., & Chrousos, G. P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0731-7 · Cited by 85
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
LonDownS Consortium, Startin, C. M., Ashton, N. J., Hamburg, S., Hithersay, R., Wiseman, F. K., Mok, K. Y., Hardy, J., Lleó, A., Lovestone, S., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0477-0 · Cited by 85
“5 times higher as may be expected based on the presence of an additional APP gene alone, suggesting that factor(s) other than APP triplication may contribute to increased Aβ concentrations [52], such as a positive feedback loop or an overloaded perivascular drainage system.”
BackgroundSelf-citationZheng, Q., Li, G., Wang, S., Zhou, Y., Liu, K., Gao, Y., Zhou, Y., Zheng, L., Zhu, L., Deng, Q., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1340 · Cited by 85
“E. W. Wolvetang, O. M. Bradfield, M. Tymms, S. Zavarsek, T. Hatzistavrou, I. Kola, P. J. Hertzog, The chromosome 21 transcription factor ETS2 transactivates the -APP promoter: Implications for Down syndrome.”
BackgroundInfluentialMouse models of neurodegeneration: Know your question, know your mouse
Fisher, E. M. C., & Bannerman, D. M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1818 · Cited by 78
Self-citationNew approaches to studying early brain development in Down syndrome
Baburamani, A. A., Patkee, P. A., Arichi, T., & Rutherford, M. A. (2019) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14260 · Cited by 74
“Whilst amyloid precursor protein (APP) is known to significantly contribute to the early-onset of Alzheimer disease, recently it has been shown that triplication of other genes on Hsa21 (Tc1 mouse is 75% trisomic for Hsa21 genes) can exacerbate plaque formation and cognitive deficits in mice.(68) Advances in chromosom…”
BackgroundZheng, Q., Song, B., Li, G., Cai, F., Wu, M., Zhao, Y., Jiang, L., Guo, T., Shen, M., Hou, H., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152170 · Cited by 73
“As one of the critical risk factors for early-onset Alzheimer’s disease (AD), trisomy 21 not only increases amyloid precursor protein (APP) gene dosage but also promotes the amyloidogenic pathway in the AD human brain by altering APP processing (1–3) and amyloid plaque deposition in the AD mouse brain (4).”
Background“Amyloid‐beta accumulation cycle” as a prevention and/or therapy target for Alzheimer's disease
Rao, C. V., Asch, A. S., Carr, D. J. J., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13109 · Cited by 71
“The mice showed increased amyloid-beta aggregation and deposition of plaques with cognitive deficits, although they showed no increase in APP abundance (Wiseman et al., 2018).”
BackgroundRevisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 76
Carmona‐Iragui, M., Videla, L., Lleó, A., & Fortea, J. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22709 · Cited by 65
“This finding suggesting that other still unidentified genes, not only APP, do also play a role on the development of AD in DS (Wiseman et al., 2018).”
BackgroundInfluentialThe Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling
Osorio, C., Kanukuntla, T., Diaz, E., Jafri, N., Cummings, M., & Sfera, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00143 · Cited by 49
Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
Montoliu‐Gaya, L., Strydom, A., Blennow, K., Zetterberg, H., & Ashton, N. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163639 · Cited by 60
“Recent perspectives have challenged whether an increased genetic dosage of APP is sufficient to explain the highly increased AD susceptibility seen in individuals with DS [10].”
BackgroundSelf-citationWright, A. L., Konen, L. M., Mockett, B. G., Morris, G. P., Singh, A., Burbano, L. E., Milham, L. T., Hoang, M., Zinn, R., Chesworth, R., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00632-5 · Cited by 50
“Previous studies have shown mice overexpressing hAPP, including J20 mice, exhibit a much larger signal in Aβ levels compared to WT mice [71, 72].”
ResultBasal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer’s Disease
Martinez, J. L., Zammit, M. D., West, N. R., Christian, B. T., & Bhattacharyya, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.703876 · Cited by 55
Belbin, O., Xiao, M.-F., Xu, D., Carmona-Iragui, M., Pegueroles, J., Benejam, B., Videla, L., Fernández, S., Barroeta, I., Nuñez-Llaves, R., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00398-0 · Cited by 39
“Down syndrome (DS) has been conceptualized by the International Working Group for Alzheimer’s disease (AD) as a genetically determined form of AD [1] due to the triplication of the gene encoding amyloid precursor protein (APP), among others [2].”
BackgroundGross, T. J., Doran, E. W., Cheema, A. K., Head, E., Lott, I. T., & Mapstone, M. E. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22716 · Cited by 44
“However, recent perspectives have challenged whether an increased genetic dosage of APP is sufficient to explain the highly increased AD susceptibility seen in individuals with DS (Ovchinnikov, Korn, Virshup, Wells, & Wolvetang, 2018; Wiseman et al., 2018).”
BackgroundUltrastructural and dynamic studies of the endosomal compartment in Down syndrome
Botté, A., Lainé, J., Xicota, L., Heiligenstein, X., Fontaine, G., Kasri, A., Rivals, I., Goh, P., Faklaris, O., Cossec, J.-C., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00956-z · Cited by 37
The Vascular-Immune Hypothesis of Alzheimer’s Disease
Mehta, R. I., & Mehta, R. I. (2023) · Biomedicines · doi:10.3390/biomedicines11020408 · Cited by 37
Gautam, D., Naik, U. P., Naik, M. U., Yadav, S. K., Chaurasia, R. N., & Dash, D. (2023) · Biomolecules · doi:10.3390/biom13111609 · Cited by 41
“The trisomy of chromosome 21, where the APP gene is located, also increases the risk of dementia in people with Down syndrome [29].”
BackgroundThe vexing complexity of the amyloidogenic pathway
Castro, M., Hadziselimovic, A., & Sanders, C. R. (2019) · Protein Science · doi:10.1002/pro.3606 · Cited by 43
Non-coding RNA influences in dementia
Ayers, D., & Scerri, C. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.09.002 · Cited by 34
The X Files: “The Mystery of X Chromosome Instability in Alzheimer’s Disease”
Bajić, V., Essack, M., Živković, L., Stewart, A. J., Zafirovic, S. S., Bajić, V. B., Gojobori, T., Isenović, E. R., & Spremo‐Potparević, B. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2019.01368 · Cited by 36
“Other GWAS, however, have been unable to confirm the existence of these connections (Beecham et al., 2010; Wu et al., 2010; Miar et al., 2011; Chung et al., 2013).”
BackgroundResultWu, C.-I., Vinton, E. A., Pearse, R. V., Heo, K., Aylward, A. J., Hsieh, Y., Bi, Y., Adeleye, S., Fancher, S. B., Duong, D. M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01454-5 · Cited by 36
Panagaki, T., Pecze, L., Randi, E. B., Nieminen, A. I., & Szabó, C. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102416 · Cited by 30
Aβ and tau prions feature in the neuropathogenesis of Down syndrome
Condello, C., Maxwell, A. M., Castillo, E., Aoyagi, A., Graff, C., Ingelsson, M., Lannfelt, L., Bird, T. D., Keene, C. D., Seeley, W. W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2212954119 · Cited by 28
d-ribose and pathogenesis of Alzheimer’s disease
Javed, M., Ahmad, M. I., Javed, H., & Naseem, S. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05243-7 · Cited by 28
Das, S., Sengupta, S., & Chakraborty, S. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00579 · Cited by 28
Martini, A. C., Gross, T. J., Head, E., & Mapstone, M. E. (2022) · Neuron · doi:10.1016/j.neuron.2022.04.001 · Cited by 28
Cutting-edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease
Inamdar, A., Gurupadayya, B., Halagali, P., Nandakumar, S., Pathak, R., Singh, H., & Sharma, H. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128344571241018154506 · Cited by 36
Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta‐analyses
Alhajraf, F., Ness, D., Hye, A., & Strydom, A. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22715 · Cited by 27
“…pathogenesis, as is suggested by findings of (a) differing amyloid deposition in animal model studies depending on the extent of the triplication (Wiseman et al., 2018), and (b) the apparent clinical and neuropathological differences between individuals with AD due to full trisomy 21 and those…”
Self-citationTosh, J. L., Rhymes, E. R., Mumford, P., Whittaker, H. T., Pulford, L. J., Noy, S. J., Cleverley, K., LonDownS Consortium, Strydom, A., Fisher, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85062-3 · Cited by 26
“(A) Significantly more α-CTF was observed in Dp(16)3Tyb;tgAPP (n = 8, 4 male and 4 female) than tgAPP (n = 8, 4 male and 4 female) controls (F(1,12) = 5.”
BackgroundSelf-citationZhou, R., Yang, G., & Shi, Y. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.09.004 · Cited by 26
Biochemistry, Secondary Protein Structure
Rehman, I., Farooq, M., & Botelho, S. C. (2020) · StatPearls · Cited by 37
Dysregulation of the Retromer Complex System in Down Syndrome
Curtis, M. E., Yu, D., & Praticò, D. (2020) · Annals of Neurology · doi:10.1002/ana.25752 · Cited by 29
“Surprisingly, we found that retromer deficiency was not primarily aging related in DS. Dysregulation of the complex was also observed in younger patient subgroups, suggesting that retromer dysfunction may begin prior to full development of AD-like pathology and cognitive symptoms in the DS population.”
BackgroundInfluentialMouse models of aneuploidy to understand chromosome disorders
Tosh, J., Tybulewicz, V., & Fisher, E. M. C. (2022) · Mammalian Genome · doi:10.1007/s00335-021-09930-z · Cited by 24
“…of DS including heart defects, memory and neuronal deficits and craniofacial dysmorphology (for example, Ahmed et al. 2013; Dunlevy et al. 2010; Haas et al. 2013; Hall et al. 2016; O’Doherty et al. 2005; Reynolds et al. 2010; Watson-Scales et al. 2018; Wiseman et al. 2018; Witton et al. 2015).”
BackgroundSelf-citationFocusing on cellular biomarkers: The endo-lysosomal pathway in Down syndrome
Botté, A., & Potier, M. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.002 · Cited by 25
Maxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A. C., DeGrado, W. F., & Condello, C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01298-0 · Cited by 23
Firdaus, Z., & Li, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111658 · Cited by 26
“The key proteins involved in AD pathogenesis are the amyloid precursor protein (APP) and microtubule-associated protein tau (MAPT), encoded by the APP gene present on chromosome 21 [17] and the MAPT gene present on chromosome 17 [18], respectively.”
BackgroundRodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches
Farrell, C., Mumford, P., & Wiseman, F. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.909669 · Cited by 22
“APP is central in the study of AD-DS, however, three-copies of other Hsa21 genes modulate aspects of AD pathology in preclinical animal models (Sheppard et al., 2012; García-Cerro et al., 2017; Naert et al., 2018; Wiseman et al., 2018; Tosh et al., 2021).”
BackgroundSelf-citationGenetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21
Mumford, P., Tosh, J., Anderle, S., Gkanatsiou Wikberg, E., Lau, G., Noy, S., Cleverley, K., Saito, T., Saido, T. C., Yu, E., et al. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.0521-22.2022 · Cited by 22
“Recent studies in preclinical systems have demonstrated that an extra copy of other genes on Hsa21 can modulate APP biology [7-10] and thus may alter the earliest stages of AD in individuals who have DS.”
InfluentialSelf-citationIllouz, T., Nicola, R., Ben-Shushan, L., Madar, R., Biragyn, A., & Okun, E. (2021) · Communications Biology · doi:10.1038/s42003-021-01851-6 · Cited by 21
Endosome Dysregulation in Down Syndrome: A Potential Contributor to Alzheimer Disease Pathology
Filippone, A., & Praticò, D. (2021) · Annals of Neurology · doi:10.1002/ana.26042 · Cited by 20
Endosomal recycling defects and neurodevelopmental disorders
Saitoh, S. (2022) · Cells · doi:10.3390/cells11010148 · Cited by 20
“Aβ is first accumulated in the endosome system in individuals with DS as well as in those with AD, indicating that endosomal trafficking including retromer is likely to play an important role in the clearance of Aβ [21].”
BackgroundCell models for Down syndrome-Alzheimer’s disease research
Wu, Y., West, N. R., Bhattacharyya, A., & Wiseman, F. K. (2022) · Neuronal Signaling · doi:10.1042/ns20210054 · Cited by 17
Self-citationZhu, B., Parsons, T., Stensen, W., Svendsen, J. S. M., Fugelli, A., & Hodge, J. J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881385 · Cited by 18
“This suggests that DYRK1A and tau pathology is a larger contributor to ADDS, than APP (Wiseman et al., 2018).”
BackgroundHawkins, K., & Duchen, M. R. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i5.236 · Cited by 18
The Association between Sex and Risk of Alzheimer’s Disease in Adults with Down Syndrome
Mhatre, P. G., Lee, J. H., Pang, D., Zigman, W. B., Tycko, B., Krinsky-McHale, S. J., Yang, Y., Silverman, W., & Schupf, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132966 · Cited by 17
“The Association between Sex and Risk of Alzheimer’s Disease in Adults with Down Syndrome.”
BackgroundInfluentialWu, Y., Mumford, P., Noy, S., Cleverley, K., Mrzyglod, A., Luo, D., van Dalen, F., Verdoes, M., Fisher, E. M. C., & Wiseman, F. K. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01632-8 · Cited by 16
Self-citationMartá-Ariza, M., Leitner, D. F., Kanshin, E., Suazo, J., Giusti Pedrosa, A., Thierry, M., Lee, E. B., Devinsky, O., Drummond, E., Fortea, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02844-z · Cited by 15
Mahernia, S., Hassanzadeh, M., Adib, M., Peytam, F., Haghighijoo, Z., Iraji, A., Mahdavi, M. R., Edraki, N., & Amanlou, M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1873861 · Cited by 16
Untangle the mystery behind DS-associated AD – Is APP the main protagonist?
Elangovan, A., Babu, H. W. S., Iyer, M., Gopalakrishnan, A. V., & Vellingiri, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101930 · Cited by 12
Sugimoto, J., Schust, D. J., Yamazaki, T., & Kudo, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-14104-1 · Cited by 12
Cleverley, K., Lee, W. C., Mumford, P., Collins, T., Rickman, M., Cunningham, T. J., Cleak, J., Mianné, J., Szoke-Kovacs, Z., Stewart, M. E., et al. (2021) · Mammalian Genome · doi:10.1007/s00335-021-09864-6 · Cited by 11
Self-citationRodriguez, E., García‐Alba, J., Novell, R., & Esteba‐Castillo, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20065096 · Cited by 16
“The risk of developing Alzheimer’s disease in people with DS (AD-DS) is greatly elevated due to the gene overexpression produced by the chromosome 21 trisomy, in which amyloid precursor protein and other gene modulations involve an accumulation of extracellular amyloid beta and neurofibrillary tangles [3,4].”
BackgroundTTC3-Mediated Protein Quality Control, A Potential Mechanism for Cognitive Impairment
Zhou, X., Chen, X., Hong, T., Zhang, M., Cai, Y., & Cui, L. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01060-z · Cited by 12
Dierssen, M., Hérault, Y., Helguera, P. R., de Lagrán, M. M., Vázquez, A. V., Christian, B. T., Carmona‐Iragui, M., Wiseman, F. K., Mobley, W. C., Fisher, E., et al. (2021) · Molecular Syndromology · doi:10.1159/000514437 · Cited by 12
“T21 (in the absence of increased APP gene dose) modifies Aβ deposition; the underlying mechanism likely includes modulating the catabolism and resultant aggregation of Aβ via an effect on Aβ 40/42 ratio [Wiseman et al., 2015, 2018].”
BackgroundSelf-citationFarrell, C., Buhidma, Y., Mumford, P., Heywood, W. E., Hällqvist, J., Flores-Aguilar, L., Andrews, E. J., Rahimzadah, N., Taso, O. S., Doran, E., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02889-0 · Cited by 9
“…preclinical models demonstrates that genes other than APP being in three copies modify aspects of DSAD, such as cognition and amyloid-β load [1, 50, 70], but more work is required to understand how the molecular processes of AD are altered by trisomy 21 in the brain of people with DS. Recent…”
Self-citationWagemann, O., Nübling, G., Martínez-Murcia, F. J., Wlasich, E., Loosli, S. V., Sandkühler, K., Stockbauer, A., Prix, C., Katzdobler, S., Petrera, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70040 · Cited by 9
Down syndrome and dementia: advances in the field
McGlinchey, E., McCallion, P., & McCarron, M. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000589 · Cited by 11
Great Expectations: Induced pluripotent stem cell technologies in neurodevelopmental impairments
Zhang, X., Li, Z., Liu, Y., & Gai, Z. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.51842 · Cited by 10
“In an international collaborative investigation, scientists at University College London and the Francis Crick Institute found that patients with Down syndrome carried genes for early-onset Alzheimer's disease (AD) [96].”
BackgroundCurtis, M. E., Smith, T., Blass, B. E., & Praticò, D. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12334 · Cited by 4
Victorino, D. B., Faber, J., Pinheiro, D. J. L. L., Scorza, F. A., de Almeida, A.-C. G., Costa, A. C. S., & Scorza, C. A. (2022) · Aging and Disease · doi:10.14336/ad.2022.0906 · Cited by 11
“Yet, recent preclinical findings have showed that the triplication of chromosome 21 genes other than APP may also increase Aβ aggregation, deposition of plaques, and worsen AD-related cognitive impairments [142].”
BackgroundMa, D., Cardoso, M. J., Zuluaga, M. A., Modat, M., Powell, N. M., Wiseman, F. K., Cleary, J. O., Sinclair, B., Harrison, I. F., Siow, B. M., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117271 · Cited by 7
“Having DS is the single biggest risk factor for sucumbing to early-onset Alzheimer’s disease (AD) ( Wiseman et al., 2009 ; heppard et al., 2012 ; Wiseman et al., 2015 ; Wiseman et al., 2018 ).”
BackgroundSelf-citationRebillat, A., Hiance‐Delahaye, A., Falquero, S., Radice, G., & Sacco, S. (2021) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2021.104068 · Cited by 8
de Oliveira, L. C., & Faria, D. D. P. (2022) · Molecules · doi:10.3390/molecules27103244 · Cited by 10
Tsuji, M., Ohshima, M., Yamamoto, Y., Saitô, S., Hattori, Y., Tanaka, E., Taguchi, A., Ihara, M., & Ogawa, Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00106 · Cited by 10
“This phenomenon is presumably due to the triplication of genes on human chromosome 21 (Wiseman et al., 2018), in which increased levels of the amyloid precursor protein (APP) gene seem to play a major role.”
BackgroundAraya, P., Niemeyer, B., Schade, K., Dunn, L. N., Waugh, K., Busquet, N., Brindley, C., Brown, C., Winkler, C., Lyford, H. R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113130 · Cited by 7
“17,18 Furthermore, it was recently reported that USP25 , a ubiquitin-specific protease encoded on HSA21, is a critical regulator of AD pathology, as it promotes β cleavage of APP and A β generation by reducing the ubiquitination and lysosomal degradation of both APP and BACE1 in DS-AD mice.”
Pizzano, S., Sterne, G. R., Veling, M. W., Xu, L. A., Hergenreder, T., & Ye, B. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049725 · Cited by 8
“Strong evidence supports the role of APP in DS-AD pathogenesis (Doran et al., 2017; Kleschevnikov et al., 2012, 2004; O ’ Doherty et al., 2005; Salehi et al., 2006; Wiseman et al., 2018).”
Yuen, S. C., Lee, S. M., & Leung, S.-W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215349 · Cited by 7
“An in vivo study demonstrated that the triplication of genes other than APP on chromosome 21 induces A (cid:2) accumulation because of impaired protein homeostasis [173].”
Advancements in machine learning and biomarker integration for prenatal Down syndrome screening
Danaei, M., Rashnavadi, H., Yeganegi, M., Dastgheib, S. A., Bahrami, R., Azizi, S., Jayervand, F., Masoudi, A., Shahbazi, A., Shiri, A., et al. (2025) · Journal of Turkish Society of Obstetric and Gynecology · doi:10.4274/tjod.galenos.2025.12689 · Cited by 8
“On the epigenetic front, modifications that drive neuroinflammation and specific proteomic changes in cerebrospinal fluid serve as potential biomarkers for cognitive decline and Alzheimer’s onset (32,33) .”
Sacco, S., Falquero, S., Bouis, C., Akkaya, M., Gallard, J., Pichot, A., Radice, G., Bazin, F., Montestruc, F., Hiance‐Delahaye, A., et al. (2022) · Journal of Intellectual Disability Research · doi:10.1111/jir.12957 · Cited by 7
The effects of Cstb duplication on APP/amyloid-β pathology and cathepsin B activity in a mouse model
Wu, Y., Whittaker, H. T., Noy, S., Cleverley, K., Brault, V., Hérault, Y., Fisher, E., & Wiseman, F. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0242236 · Cited by 6
“by crossing a trisomic Hsa21 mouse model (Tc1), which has an extra copy of 75% Hsa21 genes 51 but lacks an additional functional copy of APP, with an APP-amyloid deposition mouse model 52 (J20-tgAPP) (13-15), we found that three copies of Hsa21 genes other than APP exacerbate Aβ 53 deposition and cognitive deficits (1…”
MethodSelf-citationAlasmari, F. F., Ahmad, A., Alsanea, S., Hammad, A. M., & Al-Qerem, W. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1592277 · Cited by 9
The Hallmarks of Aneuploidy in Cancer and Congenital Syndromes
Cheng, P., Singh, K., Reeves, R. H., & Davoli, T. (2025) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-111723-103557 · Cited by 8
“Duplication of either the APP locus alone or other genes on chromosome 21 can contribute to Alzheimer disease development, cognitive decline, and dementia (153, 217).”
Li, C., Yan, Y., Stork, O., Shen, R., & Behnisch, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072909 · Cited by 7
“Following a 2-hour period, the mice were given unrestricted access to all three arms during the test phase [35,67].”
Gomes, F. D. C., Neto, J. S. D. M., Ferrari, M. D. F. R., Carlos, C. P., Goloni‐Bertollo, E. M., & Pavarino, É. C. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.06.012 · Cited by 5
Triplication of Synaptojanin 1 in Alzheimer’s Disease Pathology in Down Syndrome
Hwang, R., Dang, L. T., Chen, J., Lee, J. H., & Marquer, C. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666221202102832 · Cited by 5
What Can We Learn About Alzheimer’s Disease from People with Down Syndrome?
Maure‐Blesa, L., Rodríguez‐Baz, Í., Carmona‐Iragui, M., & Fortea, J. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_546 · Cited by 7
Cannavo, C., Tosh, J., Fisher, E., & Wiseman, F. K. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.004 · Cited by 6
Self-citationKutasi, E., Chiş, A., Vințan, M. A., Alkhzouz, C., Văduva, D. A., Catana, A. M., & Vulturar, R. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05245-1 · Cited by 5
“Additionally, RCAN1 (regulator of calcineurin 1) may influence neurodegeneration pathways, further complicating the genetic landscape affecting cognitive decline in this population [120].”
Rataj-Baniowska, M., Mumford, P., Prestia, F., Stephan, P., Beament, M., Birling, M., Lanzillotta, C., Ciafardini, L., Barone, E., Lau, G., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71498 · Cited by 3
“40 Alternative approaches have crossed DS mouse models with transgenic or gene-targeted mouse models of autosomal dominant AD (ADAD), 24,40,46,79,80 to study DSAD mechanisms.”
Self-citationCanonica, T., Kidd, E. J., Gibbins, D., Lana‐Elola, E., Fisher, E., Tybulewicz, V. L. J., & Good, M. A. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2024.1428146 · Cited by 4
Self-citationSarangi, S., Minaeva, O. V., Ledoux, D. M., Parsons, D. S., Moncaster, J. A., Black, C. A., Hollander, J., Tripodis, Y., Clark, J. I., Hunter, D. G., et al. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109818 · Cited by 3
Mantovani, D. B. D. A., Oliveira, L. C., Spelta, L. E. W., Carvalho, C. L., Forlenza, O. V., Marie, S. K. N., Buchpiguel, C. A., Coutinho, A. M., & Faria, D. D. P. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70449 · Cited by 2
Tramutola, A., Lanzillotta, C., Domenico, F. D., Barone, E., & Perluigi, M. (2026) · Antioxidants · doi:10.3390/antiox15040520 · Cited by 4
Epigenetic regulons in Alzheimer's disease
Raval, M., Mishra, S., & Tiwari, A. K. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.01.012 · Cited by 2
ALZHEIMER HASTALIĞI, RİSK FAKTÖRLERİ VE TEDAVİ
Yıldırım, N., & Eke, B. C. (2024) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1441827 · Cited by 4
Unique Pathology in the Locus Coeruleus of Individuals with Down Syndrome
Saternos, H., Hamlett, E. D., Guzman, S. J., Head, E., Granholm, A., & Ledreux, A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240043 · Cited by 4
Russell, J. K., Conley, A. C., Wilson, J. E., & NEWHOUSE, P. A. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_523 · Cited by 3
Down syndrome: a model for chromosome abnormalities
Overk, C., & Mobley, W. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00007-1 · Cited by 4
Brodtmann, A. G., & Huq, A. J. (2021) · Neurology Genetics · doi:10.1212/nxg.0000000000000610 · Cited by 2
Metadata
- Authors
- Wiseman, F. K., Pulford, L. J., Barkus, C., Liao, F., Portelius, E., Webb, R., Chávez-Gutiérrez, L., Cleverley, K., Noy, S., Sheppard, O., Collins, T., Powell, C., Sarell, C. J., Rickman, M., Choong, X., Tosh, J. L., Siganporia, C., Whittaker, H. T., Stewart, F., Szaruga, M., London Down syndrome consortium, Murphy, M. P., Blennow, K., de Strooper, B., Zetterberg, H., Bannerman, D., Holtzman, D. M., Tybulewicz, V. L. J., Fisher, E. M. C., The LonDownS Consortium, Strydom, A., Fisher, E., Nizetic, D., Hardy, J., Tybulewicz, V., & Karmiloff-Smith, A.
- Affiliations
- King's College London (GB)
- UCL Queen Square Institute of Neurology (GB)
- University of Oxford (GB)
- Washington University in St. Louis (US)
- University of Gothenburg (SE)
- University of Kentucky (US)
- VIB-KU Leuven Center for Brain and Disease Research, VIB-Leuven 3000, Center for Human Genetics, Universitaire Ziekenhuizen and LIND, KU Leuven, Leuven, Belgium
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG UK
- MRC Prion Unit (GB)
- UK Dementia Research Institute (GB)
- The LonDownS Consortium, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Denmark Hill, London, SE5 8AF, UK
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-06-26
- Volume
- 141
- Issue
- 8
- Pages
- 2457-2474
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6061702
- OpenAlex
- W2810011474
- Cited by
- 133
- References
- 68
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 22 · 2020: 20 · 2019: 16 · 2018: 4
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, cc-by)
- Lirias (submittedVersion, other-oa)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- Wellcome Trust Strategic Award (098330/Z/12/Z)
- London Down Syndrome (LonDownS) Consortium
- Wellcome Trust Joint Senior Investigators Award
- Medical Research Council (U117527252, G0601056, FC001194)
- Alzheimer’s Research UK
- Alzheimer’s Society
- Epilepsy Research UK
- Torsten Söderberg Foundation at the Royal Swedish Academy of Sciences
- Francis Crick Institute
- Cancer Research UK (FC001194)
- Wellcome Trust (FC001194)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Down syndrome, amyloid-beta deposition, amyloid plaques, Alzheimer's disease, amyloid-beta aggregation, cognitive impairment, gamma-secretase, APP, mouse model
- MeSH terms
- Alzheimer Disease, Animals, Brain, Disease Models, Animal, Down Syndrome, Female, Humans, Male, Mice, Inbred C57BL, Trisomy, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Neurofibrillary Tangles, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.